Monday, June 15, 2026

SIX-Shot Suicide Drones Are Ready, But US Ally Says They’re ‘Just Propaganda’

Defense Minister Ahn Gyu-back stated North Korea's new drones are not yet mass-produced, emphasizing ongoing analysis and countermeasures.

Super Micro Stock Soars 16% After Nasdaq Delisting Fears Fade

Super Micro Computer's stock surged 16% as Nasdaq delisting fears eased; CEO projects $40 billion revenue next fiscal year.

North Korea’s 9th Party Congress: Key Insights and Leadership Changes You Need to Know

The 9th Congress of North Korea's Workers' Party focused on governance changes, military representation, and Kim Jong Un's optimistic economic outlook.

Tag: CDMO

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Boryung Begins First Global CDMO Supply of Alimta Through Taiwan Partnership

Boryung Pharmaceutical starts supplying Alimta to Lotus, enhancing global CDMO efforts and addressing chemotherapy drug shortages.

ST Pharm Expands Global CDMO Outreach at TIDES USA and ASGCT 2026

ST Pharm showcased its CDMO capabilities at TIDES USA and ASGCT 2026, focusing on nucleic acid therapeutics and strategic partnerships.

Samsung Biologics Strengthens Global Partnerships at Decat Week 2026: Key Insights and Strategies

Samsung Biologics aims to enhance global partnerships at J.P. Morgan's Healthcare Conference 2026, showcasing its CDMO strengths.

HLB Pep Signs Deal with Japan’s ReproCELL to Supply Customized Neoantigen Peptides — The Future of Precision Medicine?

HLB PEP partners with Reprocell to supply customized neo-antigen peptides for personalized cancer treatment, targeting global markets.

Estipam Secures Record 897 Billion KRW Contract for Oligonucleotide Raw Materials: What This Means for the Asian Market

ST Pharm secures a record 89.7 billion KRW contract for oligonucleotide ingredients, enhancing its global market position.

Lotte Biologics at DCAT Week 2026: Unveiling Strategic Collaborations in Global CDMO

Lotte Biologics will attend DCAT Week in New York to pursue global CDMO partnerships and showcase its production capabilities.

Samsung Biologics CEO John Rim Poised for Third Term: What This Means for the Global CDMO Market in 2026

John Rim of Samsung Biologics aims for a third term, leading record growth and expansion into next-gen therapies amid global challenges.

Samsung Biologics: How a 56 Billion USD CDMO Leader is Shaping the Future of Biopharmaceuticals

Samsung Biologics is evolving as a leading CDMO, targeting a production capacity of 1.32M liters by 2030 after its spin-off from Bioepis.

ST Pharm’s Record Growth: How RNA-Based Therapies Are Transforming the CDMO Market in 2026

ST Pharm reports record growth in oligonucleotide CDMO, driven by rising demand for RNA-based treatments for chronic diseases.

Samsung Biologics Unveils Three-Pillar Growth Strategy: How Capacity, Portfolio, and Global Expansion Shape 2026

Samsung Biologics outlines a growth strategy focused on production, portfolio, and global expansion to enhance its CDMO position.

GAME OVER: Samsung Biologics Declares War With ‘ExellenS’—A Standard That Kills All Biotech Competition

Samsung Biologics launches ExellenS in Europe, enhancing biopharmaceutical production with standardized quality and efficiency.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.